Latest Articles

General Oncology Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

Lung Cancer In Focus: Atezolizumab for Non-small Cell Lung Cancer

In Focus: Atezolizumab for Non-small Cell Lung Cancer

Atezolizumab is the most recent in a line of immune checkpoint inhibitors approved for patients with NSCLC.

Multiple Myeloma Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients

Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients

In this question-and-answer session, Cancer Therapy Advisor asked Dr Wildes about the management of multiple myeloma among older patients.

Pancreatic Cancer Nutritional Challenges in Patients Post-Whipple Surgery

Nutritional Challenges in Patients Post-Whipple Surgery

Nutrition is a critical factor to consider both in the pre- and postoperative period for patients undergoing a Whipple procedure.

Chronic Myeloid Leukemia Atypical Chronic Myeloid Leukemia: Current Research and Treatment Strategies

Atypical Chronic Myeloid Leukemia: Current Research and Treatment Strategies

Strategies that work for patients with CML fail for aCML cases, though some new research is promising.

Breast Cancer The Role of Diet in Breast Cancer Incidence and Survival

The Role of Diet in Breast Cancer Incidence and Survival

More prospective studies are needed to determine the role of diet and the underlying mechanisms that explain dietary benefits among women with breast cancer.

General Oncology Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

Hematologic Cancers Advances in Non-precision Therapies Improve Outcomes in AML

Advances in Non-precision Therapies Improve Outcomes in AML

Study results support development of therapeutics that are targeted and based on individual genetic variants and would generalize across patient-groups in AML.

Lung Cancer Are Medicare Rules a Culprit of Low Lung Cancer Screening Rates?

Are Medicare Rules a Culprit of Low Lung Cancer Screening Rates?

Requirements for Medicare coverage of CT lung cancer screening might be a factor for low screening rates among high-risk smokers.

Skin Cancer Avelumab: A Landmark Approval in Metastatic Merkel Cell Carcinoma

Avelumab: A Landmark Approval in Metastatic Merkel Cell Carcinoma

This approval is likely to dramatically improve the otherwise dismal outcomes for patients in this clinical setting.

Bladder Cancer Bladder Cancer Treatment Is Being Revolutionized by Immunotherapy

Bladder Cancer Treatment Is Being Revolutionized by Immunotherapy

Clinical trials and drug approvals in the past several years have dramatically improved bladder cancer treatment.

Prostate Cancer Prostate Cancer: Treatment Choices and Patient-reported Outcomes

Prostate Cancer: Treatment Choices and Patient-reported Outcomes

Two recent studies provide men diagnosed with localized prostate cancer with important information about the adverse events of treatment choices.

Lymphoma Periodontal Disease: A Risk Factor for Non-Hodgkin Lymphoma?

Periodontal Disease: A Risk Factor for Non-Hodgkin Lymphoma?

More studies are needed to determine the association between periodontal disease and non-Hodgkin lymphoma.

Lymphoma Maintenance Rituximab for Follicular Lymphoma

Maintenance Rituximab for Follicular Lymphoma

A recent meta-analysis including patients from 7 trials shows that MR improves overall survival among all patients regardless of patient and disease characteristics.

General Oncology Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters